Company profile: Celsee
1.1 - Company Overview
Company description
- Provider of an easy-to-use platform for cancer research and diagnosis in the emerging liquid-biopsy field, offering an instrument system and reagent kit to separate, detect, and retrieve circulating tumor cells (CTCs) from peripheral whole blood; formerly DeNovo Sciences.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Celsee
Mustang Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for B-cell Non-Hodgkin Lymphoma, X-linked severe combined immunodeficiency (XSCID), and glioblastoma. Pipeline includes MB-106 (third-generation fully human antibody); MB-107/MB-207 (safety-modified lentiviral gene therapies for XSCID); MB-101 (IL13Rα2-targeted CAR T); MB-108 (oncolytic herpes simplex virus); and MB-109 (combining CAR T with oHSV to improve efficacy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mustang Bio company profile →
CytomX Therapeutics
HQ: United States
Website
- Description: Provider of proteolytically activated Probody therapeutics designed to activate only in cancer via tumor-specific proteases, minimizing activity in healthy tissue. Pipeline includes CX-904, a T-cell-engaging bispecific Probody targeting EGFR and CD3 in Phase 1 for advanced solid tumors; CX-2051, a conditionally activated EpCAM-targeting antibody-drug conjugate; and CX-801, an interferon alpha-2b Probody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytomX Therapeutics company profile →
Nkarta
HQ: United States
Website
- Description: Provider of a cell engineering platform for next-generation cell therapies, offering allogeneic off-the-shelf CAR-NK treatments including NKX101, an NKG2D CAR-NK for hematologic malignancies and solid tumors, and NKX019, a CD19-targeting CAR-NK for B-cell malignancies, supported by a proprietary allogeneic manufacturing process for NK cell collection, activation, engineering, expansion, and cryopreservation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nkarta company profile →
Nereus Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics discovery and development focused on oncology, infectious diseases, and inflammation, leveraging marine microbiology technologies to identify and develop drug candidates, including NPI-2358, a tumor vascular disrupting agent.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nereus Pharmaceuticals company profile →
Clinical Laserthermia Systems
HQ: Sweden
Website
- Description: Provider of the TRANBERG® Thermal Therapy System and disposable materials for image-guided, minimally invasive laser ablation and heat-induced immunotherapy (imILT®), offering focal therapy for localized prostate cancer, careful therapy of brain lesions/epileptogenic foci, immune-stimulating laser ablation, and the Thermoguide Workstation for real-time treatment monitoring and control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clinical Laserthermia Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Celsee
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Celsee
2.2 - Growth funds investing in similar companies to Celsee
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Celsee
4.2 - Public trading comparable groups for Celsee
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →